The authors also highlighted the therapeutic potential of targeting this disrupted interaction, with the stapled peptide SAH-mAH2-5 derived from N1DARP offering a promising strategy for treating Notch1-activated PC. The gene discussed is NOTCH1; the disease is pachyonychia congenita.